Status:
COMPLETED
Intraoperative vs. Postoperative Intravesical Epirubicin Instillation for Prevention of Bladder Recurrence in High-Risk Upper Urinary Tract Urothelial Carcinoma
Lead Sponsor:
Ankara Etlik City Hospital
Conditions:
Bladder Cancer Recurrence
Intravesical Instillation
Eligibility:
All Genders
Brief Summary
Upper urinary tract urothelial carcinoma (UTUC) accounts for 5%-10% of urothelial malignancies, with up to 50% of patients developing bladder recurrence post-RNU. High-risk UTUC (≥pT2, high-grade, or ...
Eligibility Criteria
Inclusion
- primary high-risk UTUC.
Exclusion
- prior bladder cancer,
- low-risk UTUC (managed conservatively),
- metastatic disease,
- incomplete follow-up
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2024
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT06941038
Start Date
June 1 2021
End Date
June 20 2024
Last Update
April 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ankara City Hospital Bilkent, Ankara, Ankara 06800
Ankara, Turkey (Türkiye), 06050